

The Risks

Infectious Bovine Rhinotracheitis (IBR) is caused by Bovine herpesvirus 1 (BoHV-1), a highly infectious virus which spreads both directly (animal to animal and over short distances through the air), and indirectly (e.g. on clothing and equipment).

INFECTION PRESENT IN 96% OF DAIRY HERDS

Infection in naïve animals can result in respiratory signs, discharge from the eyes and nose, fever, inappetance, milk drop and abortion.

Bulk milk antibody testing shows that many dairy herds in the UK are chronically infected. Animals exposed to the virus become life long carriers, and in times of stress, such as around calving, can start shedding virus. They may or may not show signs of disease at this time, but they can infect others in the herd.

The Impact

- The impact of an IBR outbreak in naïve animals is evident. The impact of living with a chronically infected herd is less so.
- Studies^{2,3} show improved annual yields of between 251 and 793 litres in uninfected cows, representing a gain of up to £132/cow/year*



The **Rispoval IBR marker vaccines** offer both convenience and a comprehensive solution to IBR protection:

- Annual herd vaccination programme
- Protection against BoHV-1 abortion
- Protection for cattle at immediate risk of IBR

For more advice and information on the Zoetis range visit us at:

www.livestockfarming.co.uk

You can also find us on Twitter and Facebook



@dairy_farmers



DairyFarmersUK

Rispoval® IBR-Marker Inactivated contains inactivated gE negative BHV-1 strain Difivac. For the active immunisation of cattle to reduce the clinical signs of IBR, reduce virus shedding, and to prevent BHV-1 associated abortions. [POM-V](#)

Rispoval® IBR-Marker Live contains attenuated gE negative BHV-1 strain Difivac. For the active immunisation of cattle to reduce the clinical signs of IBR, reduce virus shedding and to reduce BHV-1 associated abortions. [POM-V](#)

References

1. Woodbine K.A et al (2009) BMC Veterinary Research 5-5
2. Sayers R.G., (2016) Journal of Dairy Science In Press
3. Statham J. M. E., et al (2015) Veterinary Record 177: 339

*Oct-16 Promar milk minder dairy costings based on 16.7ppl margin over purchased feed

For further information please contact your vet, or Zoetis UK Ltd, Walton Oaks, Tadworth, Surrey KT20 7NS. www.zoetis.co.uk
Customer Support: 0845 300 8034
Use medicines responsibly, (www.noah.co.uk/responsible)
Date of preparation: December 2016 AH716/16

Rispoval®

IBR Marker Vaccines

Your most comprehensive solution to IBR control

- Annual herd vaccination programme
- Protection against BoHV-1 abortion
- Protection for cattle at immediate risk of IBR



zoetis

zoetis

Key reasons to use the Rispoval IBR Marker Vaccines:

Annual Herd Vaccination Programme

- The Rispoval IBR Marker vaccines have been developed with convenience in mind
- A single dose of Rispoval IBR Marker Live followed up to 6 months later with a single dose of Rispoval IBR Marker Inactivated, allows for an annual vaccination programme using a single dose of Rispoval IBR Marker Inactivated

The Rispoval IBR Marker vaccines are the only IBR vaccines licensed to provide 12 months protection from a single dose annual herd vaccination programme.

BoHV-1 Abortion Protection

- The Rispoval annual herd vaccination programme will prevent abortions due to BoHV-1
- Vaccinating heifers pre-bulling ensures protection for these vulnerable animals during their first pregnancy


The Rispoval IBR Marker vaccines are the only IBR vaccines licensed to protect against BoHV-1 abortions.

Cattle at Immediate Risk of IBR

- Rispoval IBR Marker Live is the only IBR marker vaccine licensed to be used in the face of an IBR outbreak
- Cattle at immediate risk of disease should be vaccinated intranasally and ongoing protection is ensured by following with an intramuscular dose of Rispoval IBR Marker Live 3-5 weeks later

Rispoval IBR Marker Live is the only marker vaccine licensed to protect cattle at immediate risk of disease during an IBR outbreak.

Rispoval IBR Marker Vaccine Annual Programme



Switching from a Competitor Vaccine Programme

